Effect of Ecabet Sodium Enema on mildly to moderately active ulcerative proctosigmoiditis: an open-label study

No abstract is available for this paper.

• Publication year

  2001

• Venue

  American Journal of Gastroenterology

• Publication date

  2001-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1572-0241.2001.03624.xPMID 11280553
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Possible Mechanism of Increase in Gastric Mucosal PGE2 and PGI2 Generation Induced by Ecabet Sodium, a Novel Gastroprotective Agent

  2004cited by this paper
• Effects of Ecabet Sodium, a Novel Gastroprotective Agent, on Mucin Metabolism in Rat Gastric Mucosa

  2000cited by this paper
• Low Endogenous Prostaglandin E2 Predisposes to Relapsing Inflammation in Experimental Rat Enterocolitis

  1999cited by this paper
• Sucralfate and Methylprednisolone Enemas in Active Ulcerative Colitis (A Prospective, Single-Blind Study)

  1999cited by this paper
• Review article: the potential role of nitric oxide in chronic inflammatory bowel disorders

  1999cited by this paper
• Centrifugal leukocyte apheresis for ulcerative colitis.

  1998cited by this paper
• Nitric Oxide as a Modulator of Intestinal Water and Electrolyte Transport

  1998cited by this paper
• Prospective evaluation of a new anti‐ulcer agent, ecabet sodium, for the treatment of Helicobacter pylori infection

  1998cited by this paper
• A Practical Guide to the Management of Distal Ulcerative Colitis

  1998cited by this paper
• Effects of chemical sympathectomy and sensory nerve ablation on experimental colitis in the rat.

  1997cited by this paper
• Rectal distention-induced colonic net water secretion in rats involves tachykinins, capsaicin sensory, and vagus nerves.

  1997cited by this paper
• Control of tobacco smoke and odors using discharge plasma reactor

  1997cited by this paper
• Capsaicin and the stomach. A review of experimental and clinical data.

  1997cited by this paper
• Nitric oxide--a mediator of inflammation or mucosal defence.

  1997cited by this paper
• Treatment of left‐sided ulcerative colitis with butyrate enemas: a controlled trial

  1996cited by this paper
• Treatment of distal ulcerative colitis with short-chain fatty acid enemas a placebo-controlled trial

  1996cited by this paper
• Treatment of refractory distal ulcerative colitis with short chain fatty acid enemas.

  1996cited by this paper
• Sucralfate and hydrocortisone enemas in the treatment of active ulcerative proctitis—a randomized single‐blind comparative study

  1996cited by this paper
• Short‐chain fatty acid topical treatment in distal ulcerative colitis

  1995cited by this paper
• Roles of prostaglandins, nitric oxide and the capsaicin-sensitive sensory nerves in gastroprotection produced by ecabet sodium.

  1995cited by this paper
• A placebo-controlled trial of cyclosporine enemas for mildly to moderately active left-sided ulcerative colitis.

  1994cited by this paper
• Role of 5-HT3 receptors and afferent fibers in the effects of mast cell degranulation on colonic motility in rats.

  1994cited by this paper
• Treatment of refractory ulcerative proctosigmoiditis with butyrate enemas.

  1994cited by this paper
• Effects of cyclooxygenase and lipoxygenase inhibition on eicosanoids and healing of acetic acid colitis in rats

  1993cited by this paper
• Cyclosporine enemas for treatment-resistant, mildly to moderately active, left-sided ulcerative colitis.

  1993cited by this paper
• Short-chain fatty acid enemas: A cost-effective alternative in the treatment of nonspecific proctosigmoiditis

  1992cited by this paper
• Microscopic activity in ulcerative colitis: what does it mean?

  1991cited by this paper
• Ion exchange chromatography of purified colonic mucus glycoproteins in inflammatory bowel disease: absence of a selective subclass defect.

  1991cited by this paper
• Metabolic fate of a new anti-ulcer drug (+)-(1R,4aS,10aR)-1,2,3,4,4a,9,10,10a- octahydro-1,4a-dimethyl-7-(1-methylethyl)-6-sulfo-1- phenanthrenecarboxylic acid 6-sodium salt pentahydrate (TA-2711). II. Distribution in the rat stomach.

  1991cited by this paper
• Sucralfate enema in ulcerative rectosigmoid lesions

  1990cited by this paper
• Effects of 12-sulfodehydroabietic acid monosodium salt (TA-2711), a new anti-ulcer agent, on gastric mucosal lesions induced by necrotizing agents and gastric mucosal defensive factors in rats.

  1990cited by this paper
• Mucin depletion in inflammatory bowel disease.

  1990cited by this paper
• Effects of 12-sulfodehydroabietic acid monosodium salt (TA-2711), a new anti-ulcer agent, on gastric secretion and experimental ulcers in rats.

  1989cited by this paper
• Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial.

  1989influential reference
• Effects of 16,16-dimethyl prostaglandin E2 and indomethacin on leukotriene B4 and inflammation in rabbit colitis.

  1988cited by this paper
• Sucralfate enema (SUC)--effective in IBD?

  1986cited by this paper
• 5-Aminosalicylic acid enemas in refractory distal ulcerative colitis: a randomized, controlled trial.

  1986cited by this paper
• Effects of sulphasalazine and disodium azodisalicylate on colonic PGE2 concentrations determined by equilibrium in vivo dialysis of faeces in patients with ulcerative colitis and healthy controls.

  1984cited by this paper

• Antioxidant and Anti-Inflammatory Phytochemicals for the Treatment of Inflammatory Bowel Disease: A Systematic Review

  2024cites this paper
• Personalize, participate, predict, and prevent: 4Ps in inflammatory bowel disease

  2023cites this paper
• Refractory Proctitis

  2019cites this paper
• Ulcerative Proctitis and Anorectal Crohn’s Disease

  2018cites this paper
• The treatment of refractory ulcerative colitis.

  2018cites this paper
• Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management.

  2017cites this paper
• [Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management (Spanish version)].

  2015cites this paper
• Novel Nonbiologic Therapies for Ulcerative Colitis

  2014cites this paper
• Histologic Evaluation of Ulcerative Colitis: A Systematic Review of Disease Activity Indices

  2014cites this paper
• What is left when anti-tumour necrosis factor therapy in inflammatory bowel diseases fails?

  2014cites this paper
• Efficacy of zinc–carnosine chelate compound, Polaprezinc, enemas in patients with ulcerative colitis

  2014cites this paper
• Ulcerative proctitis: an update on the pharmacotherapy and management

  2014cites this paper
• Safety and Tolerability of Bismuthyl Ecabet Suspension, a Novel Anti-Ulcer Agent, following Single and Multiple Oral Dose Administration in Healthy Chinese Subjects

  2012cites this paper
• Second European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Current management

  2012cites this paper
• Placebo controlled evaluation of Xilei San, a herbal preparation in patients with intractable ulcerative proctitis

  2012cites this paper
• Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management.

  2012cites this paper
• Topical agents for idiopathic distal colitis and proctitis

  2011cites this paper
• Ecabet sodium: A potential new agent in the management of distal colitis

  2010cites this paper
• Ecabet sodium promotes the healing of trinitrobenzene‐sulfonic‐acid‐induced ulceration by enhanced restitution of intestinal epithelial cells

  2010cites this paper
• Novel topical therapies for distal colitis.

  2010cites this paper
• Prisons, prisoners, and hepatitis C

  2010cites this paper
• Efficacy of ecabet sodium enema on intractable rectal ulcer after piecemeal endoscopic mucosal resection for rectal tumor

  2010cites this paper
• RE‐EPITHELIALIZATION OF SQUAMOUS EPITHELIUM FOR A RADIATION‐INDUCED RECTAL ULCER WHILE GIVING AN ECABET SODIUM ENEMA

  2009cites this paper
• Effects of Ecabet Sodium on Acute Mixed Reflux Esophagitis in Rats

  2009cites this paper
• [Relapse rates of ulcerative colitis in remission and factors related to relapse].

  2008cites this paper
• European evidence-based Consensus on the management of ulcerative colitis: Current management.

  2008cites this paper
• European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Definitions and diagnosis.

  2008cites this paper
• Mobilization of Bone Marrow Cells by Leukocytapheresis in Patients With Ulcerative Colitis

  2008cites this paper
• Drug evaluation: TA-2711E in the treatment of active distal ulcerative colitis.

  2007cites this paper
• High Affinity of Ecabet Sodium for Inflamed Colonic Mucosa in Ulcerative Colitis

  2007cites this paper
• Efficacy of ecabet sodium enema on steroid resistant or steroid dependent ulcerative colitis

  2006cites this paper
• Efficacy and safety of ecabet sodium on functional dyspepsia: a prospective, double-blinded, randomized, multi-center controlled trial.

  2006cites this paper
• Diagnosis of lymphogranuloma venereum from biopsy samples

  2006cites this paper
• A case of radiation colitis improved with ecabet sodium enema

  2005cites this paper
• Ecabet sodium prevents the delay of wound repair in intestinal epithelial cells induced by hydrogen peroxide

  2005cites this paper
• Therapeutic Effects of Ecabet Sodium, an Antiulcer Drug, on Dextran Sodium Sulfate–Induced Ulcerative Colitis in Rats

  2005influential citation
• Ecabet sodium raises plasma levels of calcitonin gene‐related peptide and substance P in healthy humans

  2005cites this paper
• Immunomodulatory therapy for inflammatory bowel disease

  2004cites this paper
• Acetic acid-derived prostaglandin-dependent colonic adaptive cytoprotection is preserved in chronic colitis: role of cyclo-oxygenase

  2003cites this paper
• Ecabet sodium attenuates reactive oxygen species produced by neutrophils after priming with bacterial lipopolysaccharides.

  2003cites this paper
• Current Medical Treatment for Inflammatory Bowel Disease

  2003cites this paper
• Epidermal growth factor for ulcerative colitis.

  2003cites this paper
• Evolving medical therapies for ulcerative colitis

  2002cites this paper
• Adaptive cytoprotection against acetic acid induced colonic injury in rats

  2001cites this paper
• Evolving medical therapies for ulcerative colitis

  2001cites this paper